Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer

Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany

VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer ( Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany )

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration...

Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands

CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer ( Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands )

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer

Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer ( Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain )

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced...

Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain

CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )

Checkmate 227: Final analysis for the non small cell lung cancer trial

Prof Sanjay Popat - The Royal Marsden Hospital, London, UK

Checkmate 227: Final analysis for the non small cell lung cancer trial ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )

PARP inhibitors for metastatic breast cancer

Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany

PARP inhibitors for metastatic breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer

Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of...

TRITON2: Rucaparib for metastatic castration-resistant prostate cancer ( Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Ireland )

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC

Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA

Nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC ( Prof Ahmed Kaseb - MD Anderson Cancer Center, Houston, USA )

Association between tTMB and clinical outcomes with pembrolizumab alone in PD...

Prof Roy Herbst - Yale Cancer Center, New Haven, USA

Association between tTMB and clinical outcomes with pembrolizumab alone in PD-L1-positive advanced NSCLC in KEYNOTE-010 and -042 ( Prof Roy Herbst - Yale Cancer Center, New Haven, USA )

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer

Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain

IMPALA results: Lefitolimod vs standard of care in metastatic colorectal cancer ( Dr Ramon Salazar - Catalan Institute of Oncology, Barcelona, Spain )

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours

Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA

AMG 510: A novel molecule targeting KRAS G12C mutant solid tumours ( Prof Marwan Fakih - City of Hope National Medical Center, Duarte, USA )

Blood first assay screening in patients with ALK positive NSCLC

Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA

Blood first assay screening in patients with ALK positive NSCLC ( Prof Shirish Gadgeel - University of Michigan, Ann Arbor, USA )

More from ecancer